Regenxbio maintained at Buy rating by H.C. Wainwright post …

1 day ago · H.C. Wainwright's analysts kept the $36.00 price target and cited the strategic partnership and the progress of Regenxbio's gene therapy candidates as key factors in …

$36.00
OFF

Regenxbio Maintained At Buy Rating By H.C. Wainwright Post …

2 weeks from now

1 day ago · H.C. Wainwright's analysts kept the $36.00 price target and cited the strategic partnership and the progress of Regenxbio's gene therapy candidates as key factors in …

investing.com

$36.00
OFF

RegenXBio: Strategic Partnerships And Promising Pipeline Drive …

2 weeks from now

1 day ago · Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $36.00. Discover outperforming stocks and …

businessinsider.com

$36.00
OFF

Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

2 weeks from now

17 hours ago · Ratings for Regenxbio RGNX were provided by 7 analysts in the past three months, ... HC Wainwright & Co. Maintains: Buy: $36.00: $36.00: Luca Issi: RBC Capital: …

benzinga.com

45%
OFF

H.C. Wainwright Sees 45% Approval Probability For RGX-202, …

2 weeks from now

Nov 21, 2024 · On Thursday, H.C. Wainwright adjusted its price target for NASDAQ:RGNX, Regenxbio Inc (NASDAQ: RGNX)., to $36 from the previous $40, while reaffirming a Buy …

investing.com

$36
OFF

Regenxbio Price Target Lowered To $36 From $40 At H.C. Wainwright

2 weeks from now

Nov 21, 2024 · H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio to $36 from $40 and keeps a Buy rating on the shares after the company reported the first …

businessinsider.com

$38.00
OFF

Positive Clinical Advancements Reinforce Buy Rating For …

2 weeks from now

Jun 20, 2024 · Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on RegenXBio (RGNX – Research Report).The associated price target remains the same with $38.00. Yi …

businessinsider.com

$39.00
OFF

What 4 Analyst Ratings Have To Say About Regenxbio

2 weeks from now

Oct 10, 2024 · In the preceding three months, 4 analysts have released ratings for Regenxbio (NASDAQ:RGNX), ... HC Wainwright & Co. Raises: Buy: $39.00: $38.00: Key Insights: Action …

nasdaq.com

$39.00
OFF

Regenxbio Shares Keep Buy Rating, Price Target On Trial Data

2 weeks from now

Sep 5, 2024 · On Thursday, H.C. Wainwright maintained a Buy rating and a stock price target of $39.00 on Regenxbio Inc. (NASDAQ:RGNX), following the announcement of new long-term …

investing.com

$36.00
OFF

H.C. Wainwright Reiterates Buy Rating On Regenxbio Inc. (RGNX)

2 weeks from now

17 hours ago · H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $36.00 price target on Regenxbio Inc. (NASDAQ: RGNX).The analyst commented: "Yesterday, REGENXBIO …

streetinsider.com

45%
OFF

H.C. Wainwright Sees 45% Approval Probability For RGX-202, …

2 weeks from now

Nov 21, 2024 · On Thursday, H.C. Wainwright adjusted its price target for NASDAQ:RGNX, Regenxbio Inc (NASDAQ: RGNX)., to $36 from the previous $40, while reaffirming a Buy …

investing.com

$40.00
OFF

5 Analysts Have This To Say About Regenxbio | Nasdaq

2 weeks from now

Nov 15, 2024 · HC Wainwright & Co. Raises: Buy: $40.00: $39.00: Daniil Gataulin: Chardan Capital: Maintains: Buy: ... Stay informed and make data-driven decisions with our Ratings …

nasdaq.com

$40.00
OFF

HC Wainwright Issues Pessimistic Forecast For REGENXBIO

2 weeks from now

Nov 21, 2024 · HC Wainwright cut their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating on the stock in a research report on Thursday. ...

marketbeat.com

$38.00
OFF

H.C. Wainwright Sees FDA Update As 'bullish' In Regenxbio Stock Re ...

2 weeks from now

Jun 21, 2024 · On Friday, Regenxbio Inc. (NASDAQ:RGNX) stock maintained its Buy rating and a $38.00 price target from H.C. Wainwright. This affirmation follows the company's recent …

investing.com

$38.00
OFF

H.C. Wainwright Sees FDA Update As 'bullish' In Regenxbio Stock Re ...

2 weeks from now

Jun 21, 2024 · On Friday, Regenxbio Inc. (NASDAQ:RGNX) stock maintained its Buy rating and a $38.00 price target from H.C. Wainwright. This affirmation follows the company's recent …

investing.com

$940000
OFF

8516 3rd Ave, North Bergen, NJ 07047 - Zillow

2 weeks from now

Dec 3, 2024 · 8516 3rd Ave, North Bergen NJ, is a Multiple Occupancy home.It contains 6 bedrooms and 4 bathrooms.This home last sold for $940,000 in December 2024. The …

zillow.com

$39
OFF

Buy Rating Affirmed By Analyst On RegenXBio’s Promising …

2 weeks from now

Sep 11, 2024 · Regenxbio price target raised to $39 from $38 at H.C. Wainwright Regenxbio price target lowered to $50 from $55 at Barclays Regenxbio reports Q2 EPS ($1.05), consensus ($1.29)

businessinsider.com

$599000
OFF

1205 50th St, North Bergen, NJ 07047 | MLS #240021836 - Zillow

2 weeks from now

Nov 18, 2024 · Zillow has 37 photos of this $599,000 3 beds, 3 baths, -- sqft single family home located at 1205 50th St, North Bergen, NJ 07047 MLS #240021836.

zillow.com

$299999
OFF

9249 John F Kennedy Blvd #104, North Bergen, NJ 07047

2 weeks from now

Oct 8, 2024 · Zillow has 18 photos of this $299,999 2 beds, 2 baths, 1,200 Square Feet condo home located at 9249 John F Kennedy Blvd #104, North Bergen, NJ 07047 MLS #240019869.

zillow.com

$70.00
OFF

RBC Capital Sticks To Its Buy Rating For Ionis Pharmaceuticals (IONS)

2 weeks from now

1 day ago · RBC Capital analyst Luca Issi reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $70.00. The company’s shares closed …

businessinsider.com

$909999
OFF

8100 River Rd #6017, North Bergen, NJ 07047 | Zillow

2 weeks from now

Oct 21, 2024 · Zillow has 10 photos of this $909,999 2 beds, 2 baths, 1,530 Square Feet condo home located at 8100 River Rd #6017, North Bergen, NJ 07047 built in 2008.

zillow.com

FAQs about Regenxbio maintained at Buy rating by H.C. Wainwright post … Coupon?

Is it a good buy to invest in REGENXBIO?

According to analysts, REGENXBIO is a Moderate Buy. The average rating score is 2.83, based on 10 buy ratings, 2 hold ratings, and no sell ratings. The consensus price target is $38.00, which represents a forecasted upside of 71.2% from its current price of $22.19. The title of the article is 'REGENXBIO (RGNX) Stock Price, News & Analysis - MarketBeat'. ...

What is the target price for regenxbio?

The associated price target remains the same with $38.00. Yi Chen has given his Buy rating due to a combination of factors surrounding RegenXBio’s progress and expectations in its clinical trials and regulatory submissions. ...

Should you buy regenxbio (rgx-202)?

With a pivotal trial for RGX-202 anticipated to commence between late 2024 and early 2025, Yi Chen sees these developments as substantial grounds for the Buy rating and maintains a $38 price target for RegenXBio’s stock. According to TipRanks, Chen is an analyst with an average return of -26.4% and a 22.92% success rate. ...

Is regenxbio's $370m upfront payment a good deal?

As for Regenxbio, the company enjoyed the $370M in an upfront cash payment. You can view cash as the blood of a young company like Regenxbio. In other words, cash is life and king. And, the cash upfront payment was indeed sizable. Additionally, the deal term was quite favorable because Regenxbio is positioned to gain $1. 38B for this deal. ...

Who is the co-founder of Regenxbio?

Regenxbio co-founder Jim Wilson is an inventor on the patent in question, which was granted in the U.S. in January. The patent was originally owned by the University of Pennsylvania, which is also a party to the lawsuit, according to the news report. ...

What does regenxbio stand for?

RegenXBio (RGNX) Company Description: REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. ...